CBDV ( DrugBank: CBDV )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 1 |
193. プラダー・ウィリ症候群
臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03848481 (ClinicalTrials.gov) | November 23, 2020 | 19/2/2019 | CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) | Cannabidivarin (CBDV) vs. Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) | Prader-Willi Syndrome | Drug: CBDV Compound;Drug: Placebo | Montefiore Medical Center | Foundation for Prader-Willi Research;GW Pharmaceuticals Ltd. | Recruiting | 5 Years | 30 Years | All | 26 | Phase 2 | United States |